TABLE 6.
Plasma metabolites levels in patients with primary DCM that were not treated with a specific heart failure medication
| No β blockers (N=7) | No ACE inhibitor (N=13) |
No Furosemide (N=13) |
No aldosterone receptor blockers (N=36) |
No Digoxin (N=23) |
|---|---|---|---|---|
| Androsterone sulfate | 1- linoleoylglycerop hosphocholine |
Glutamine | 5alpha-pregnan-3beta,20alpha- diol disulfate |
5alpha-pregnan- 3beta,20alpha-diol disulfate |
| Dehydroisoandrosterone sulfate (DHEA-S) |
Iminodiacetate (IDA) | Stearidonate (18:4n3) | ||
| Epiandrosterone sulfate | Deoxycholate | Deoxycholate | ||
| 4-androsten-3beta,17beta- diol monosulfate 1 |
Stearidonate (18:4n3) | Iminodiacetate (IDA) | ||
| Deoxycholate | Paraxanthine | Paraxanthine | ||
| 4-androsten-3beta,17beta- diol disulfate 1 |
2- linoleoylglycerophosphoethanol amine |
Linolenate [α or γ; (18:3n3 or 6)] |
||
| Pregn steroid monosulfate | Dehydroisoandrosterone sulfate (DHEA-S) |
docosapentaenoate (n3 DPA; 22:5n3) |
||
| Histidine | Indolepropionate | Dehydroisoandrosterone sulfate (DHEA-S) |
||
| Gamma-glutamylisoleucine | 1- heptadecanoylglycerophosphoc holine |
dihomo-linoleate (20:2n6) | ||
| Acetylcarnitine | 1- oleoylglycerophosphoethanola mine |
epiandrosterone sulfate | ||
| Choline | Linolenate [α or γ; (18:3n3 or 6)] |
2- linoleoylglycerophosphoethano lamine* |
||
| 2-methylbutyroylcarnitine | γ-tocopherol | oleate (18:1n9) | ||
| Erythronate | Pregn steroid monosulfate | Linoleate (18:2n6) | ||
| Erythritol | 1- linoleoylglycerophosphocholine |
Margarate (17:0) | ||
| Pseudouridine | 1- linoleoylglycerophosphoethanol amine |
10-heptadecenoate (17:1n7) | ||
| Bilirubin (Z,Z) | Stearate (18:0) | Indolepropionate | ||
| Glycocholenate sulfate* | 1- stearoylglycerophosphocholine |
Pregn steroid monosulfate | ||
| Pro-hydroxy-pro | Linoleate (18:2n6) | Stearate (18:0) | ||
| 4-acetamidobutanoate | Nonadecanoate (19:0) | Myristate (14:0) | ||
| Myo-inositol | Threonine | 1- linoleoylglycerophosphocholin e |
||
| 3-methylhistidine | 1-oleoylglycerophosphocholine | 1- eicosatrienoylglycerophosphoc holine |
||
| Taurocholenate sulfate | Glutamine | Palmitate (16:0) | ||
| Stachydrine | Phenylalanine | 1-palmitoylglycerol (1- monopalmitin) |
||
| Methylglutaroylcarnitine | Choline | Nonadecanoate (19:0) | ||
| 7-alpha-hydroxy-3-oxo-4- cholestenoate (7-Hoca) |
Threonine | |||
| Erythronate | Dihomo-linolenate (20:3n3 or n6) |
|||
| Kynurenine | Glutamine | |||
| Pseudouridine | Choline | |||
| 2-hydroxybutyrate (AHB) | 7-α-hydroxy-3-oxo-4- cholestenoate (7-Hoca) |
|||
| 3-(4-hydroxyphenyl)lactate | Xanthine | |||
| C-glycosyltryptophan | Erythronate | |||
| 4-acetamidobutanoate | Pyruvate | |||
| Pro-hydroxy-pro | Erythritol | |||
| Creatine | Pseudouridine | |||
| 3-methylhistidine | Urea | |||
| Myo-inositol | 3-(4-hydroxyphenyl)lactate | |||
| α-ketoglutarate | C-glycosyltryptophan | |||
| Cortisol | Creatine | |||
| Glutamate | Pro-hydroxy-pro | |||
| [H]HWESASLLR[OH] | 4-acetamidobutanoate | |||
| Stachydrine | Myo-inositol | |||
| Taurocholenate sulfate | α-ketoglutarate | |||
| Methylglutaroylcarnitine | Cortisol | |||
| Taurocholenate sulfate | ||||
| Methylglutaroylcarnitine |
Figure legend: Blue and red colors indicate plasma metabolites that were reduced or increased, respectively, in patients with primary DCM who were not treated with a specific heart failure medication as compared to controls (q<0.05).